Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (formerly NASDAQ: LUMO) has communicated that it is a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, with particular emphasis on Pediatric Growth Hormone Deficiency (PGHD). News about Lumos Pharma has frequently centered on the development of its lead candidate, LUM-201, an oral growth hormone secretagogue, and on key corporate milestones.
Company press releases describe a series of clinical updates from the Phase 2 OraGrowtH210 and OraGrowtH212 trials, where LUM-201 is being evaluated in children with moderate PGHD. These updates have highlighted growth outcomes, biomarker changes in IGF-1 and IGFBP-3, and detailed analyses of pulsatile growth hormone secretion patterns under LUM-201 treatment. Lumos Pharma has also reported presentations of these data at major endocrinology and pediatric endocrine conferences in regions including Europe, Latin America, and the Asia-Pacific.
In addition to clinical data, Lumos Pharma’s news flow has included information about regulatory interactions, such as its End of Phase 2 Meeting with the U.S. Food and Drug Administration regarding a potential placebo-controlled Phase 3 trial of LUM-201 in moderate PGHD. Financial updates, including quarterly results and cash position discussions, have also been part of the company’s public communications during its time as a listed entity.
A significant corporate development reported in the news is the successful completion of a tender offer and merger with Double Point Ventures LLC, after which Lumos Pharma’s common stock ceased trading on NASDAQ and the company began operating as a standalone business of Double Point Ventures. For readers reviewing the LUMO news archive, these items collectively provide historical context on Lumos Pharma’s clinical progress, regulatory discussions, financial reporting, and transition from a public company to a privately held business.
Lumos Pharma (NASDAQ: LUMO) is holding a Virtual KOL Event today, April 27, 2021, at 10:30 AM ET, featuring new data on its lead asset, LUM-201, for pediatric growth hormone deficiency (PGHD).
KOLs will present findings from the Merck 020 study, highlighting LUM-201's efficacy in increasing pulsatile growth hormone release. Data demonstrates that PEM-positive subjects experienced significant height velocity increases, while one PEM-negative subject showed no benefits.
The event will include corporate updates and a Q&A session.
Lumos Pharma announces key executive changes as of April 20, 2021, marking a year since its merger. Carl Langren, CFO since November 2018, will retire on July 4, 2021, transitioning to a consulting role. Lori Lawley, with over 14 years of experience, will succeed him. Additionally, Eddie L. Varnado joins as Vice President of Finance and Corporate Controller, bringing 15 years of expertise in the biomedical sector. The leadership changes aim to strengthen Lumos' financial strategy as it advances clinical programs for its lead candidate, LUM-201, targeting pediatric growth hormone deficiency.
Lumos Pharma (NASDAQ: LUMO) is set to host a key opinion leader webinar on LUM-201 for treating pediatric growth hormone deficiency on April 27, 2021, at 10:30 AM ET. The event will feature presentations from renowned experts Dr. Bradley S. Miller and Dr. Fernando Cassorla, discussing available treatments and unmet needs in PGHD. LUM-201 is a promising oral therapy aiming to increase GH secretion while reducing the need for injections. A corporate update will also be presented, showcasing its clinical program.
Lumos Pharma (NASDAQ: LUMO) announced enhanced results for LUM-201 in treating pediatric growth hormone deficiency (PGHD) at the ENDO 2021 conference.
The data revealed that LUM-201 elicited a significant peak growth hormone (GH) response of 15.0 ng/mL in children, outperforming standard GH secretagogues, which achieved 5.4 ng/mL. Notably, this study involved 68 prepubertal children, indicating LUM-201's therapeutic potential for about 60% of the PGHD population. LUM-201's promising results support its continued development as an alternative to daily injections.
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO) announces participation in several virtual investor conferences in March 2021. Highlights include:
- H.C. Wainwright Global Life Sciences Conference on March 10, 2021 with a pre-recorded presentation.
- Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 with a live presentation and one-on-one meetings.
- 33rd Annual Roth Conference on March 15-17, 2021 featuring presentations and meetings.
Lumos Pharma focuses on developing therapeutics for rare diseases and is evaluating LUM-201 for Pediatric Growth Hormone Deficiency.
Lumos Pharma, Inc. (NASDAQ:LUMO) reported financial results for 2020, highlighting significant achievements including the completion of a merger and the receipt of $26 million from a PRV sale.
They initiated the Phase 2b OraGrowtH210 Trial for LUM-201 targeting pediatric growth hormone deficiency (PGHD). Key insights from studies published in the Journal of Endocrine Society show predictive enrichment markers for patient enrollment in clinical trials. The company anticipates a net loss of $5.7 million for 2020, a decrease from $9.7 million in 2019, with ongoing plans for research and development.
Lumos Pharma has announced the publication of analyses supporting the use of Predictive Enrichment Markers (PEMs) in its ongoing Phase 2b OraGrowtH210 Trial for treating Pediatric Growth Hormone Deficiency (PGHD). Data from previous studies identified two PEMs: a baseline IGF-1 level > 30 ng/ml and peak GH level ≥ 5 ng/mL. The findings indicate that about 60% of diagnosed children with GHD meet PEM criteria, suggesting a targeted patient population for LUM-201 treatment. The company aims to establish an oral alternative to current injection therapies.
Lumos Pharma (NASDAQ:LUMO) will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting from March 20-23, 2021. The presentation titled LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency will be held on March 20, 2021, at 11:00AM ET. LUM-201 is a promising oral therapy for Pediatric Growth Hormone Deficiency, currently undergoing a Phase 2b clinical trial.
Lumos Pharma (NASDAQ:LUMO) will report its full year 2020 financial results on March 9, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and provide updates on clinical and corporate activities. Investors can access the live audio via a provided link or by phone. Lumos Pharma focuses on therapeutics for rare diseases, with its lead candidate LUM-201 under evaluation for Pediatric Growth Hormone Deficiency in a Phase 2b trial. The company has received Orphan Drug Designation for LUM-201 in both the US and EU.
Lumos Pharma has appointed An van Es-Johansson, M.D., to its Board of Directors, effective immediately. With over 30 years of experience in rare diseases and clinical development, she will bring valuable expertise as Lumos focuses on its Phase 2b trial for the treatment of pediatric growth hormone deficiency. Dr. van Es-Johansson succeeds Emmett Cunningham, who is resigning to concentrate on his role at Blackstone Life Sciences. The leadership change is expected to enhance Lumos Pharma’s strategic direction and clinical programs.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
